Les effets indésirables liés au traitement et la surveillance des patients recevant un traitement biologique ou à base de petites molécules pour une maladie inflammatoire de l’intestin
Résumé
La prise en charge des maladies inflammatoires de l’intestin (MII) a évolué avec l’apparition de nouveaux paradigmes thérapeutiques et l’introduction de nouveaux traitements innovants, notamment les anticorps monoclonaux (AcM) et les petites molécules. Ces traitements innovants ont permis de mieux maîtriser la maladie, mais ils nécessitent une évaluation minutieuse avant de les instaurer et une surveillance continue afin de prendre en charge les effets indésirables potentiels et optimiser les résultats des patients. Cet examen se concentre sur les approches pratiques de la surveillance spécifique des traitements innovants actuellement disponibles.
Références
Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108(8):1268-1276. doi:10.1038/ajg.2013.138
Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. European Respiratory Journal. 2010;36(5):1185-1206. doi:10.1183/09031936.00028510
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Jr., et al. Infliximab for Crohn's disease: more than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24(3):490-501. doi:10.1093/ibd/izx072
Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: metaanalysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644-653. doi:10.1016/j.cgh.2008.03.014
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-721. doi:10.1056/NEJMoa1215739
Shah ED, Farida JP, Siegel CA, Chong K, Melmed GY. Risk for overall infection with anti-TNF and anti-integrin agents used in IBD: a systematic review and meta-analysis. Inflamm Bowel Dis. 2017;23(4):570-577. doi:10.1097/mib.0000000000001049
Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(12):1227-1236. doi:10.1111/apt.13215
Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017;66(5):839-851. doi:10.1136/gutjnl-2015-311079
Loftus EV, Jr., Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1353-1365. doi:10.1111/apt.16060
Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, et al. Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study. J Crohns Colitis. 2021;15(10):1694-1706. doi:10.1093/ecco-jcc/jjab058
Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2022;20(3):578-590.e574. doi:10.1016/j.cgh.2021.02.025
Gebeyehu GG, Fiske J, Liu E, Limdi JK, Broglio G, Selinger C, et al. Ustekinumab and vedolizumab are equally safe and effective in elderly Crohn's disease patients. Dig Dis Sci. 2023;68(5):1983-1994. doi:10.1007/s10620-022-07770-8
Cheng D, Kochar BD, Cai T, Ananthakrishnan AN. Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor α antagonists in inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2022;20(10):2366-2372.e2366. doi:10.1016/j.cgh.2022.01.013
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015-2030. doi:10.1016/s0140-6736(22)00467-6
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebocontrolled withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031-2046. doi:10.1016/s0140- 6736(22)00466-4
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444-2455. doi:10.1056/NEJMoa2207940
Panés J, D'Haens GR, Sands BE, Ng SC, Lawendy N, Kulisek N, et al. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European Gastroenterol J. 2024. doi:10.1002/ueg2.12584
Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1). doi:10.1136/rmdopen-2022-002735
Din S, Selinger CP, Black CJ, Ford AC. Systematic reviewwith network meta-analysis: risk of Herpes Zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(6):666-675. doi:10.1111/apt.17379
Winthrop KL, Vermeire S, Long MD, Panés J, Ng SC, Kulisek N, et al. Long-term risk of Herpes Zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2023;29(1):85-96. doi:10.1093/ibd/izac063
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280-1291. doi:10.1056/NEJMoa2033617
Danese S, Panaccione R, Abreu MT, Rubin DT, Ghosh S, Dignass A, et al. Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension. J Crohns Colitis. 2024;18(2):264-274. doi:10.1093/ecco-jcc/jjad146
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, et al. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Mult Scler. 2022;28(12):1944-1962. doi:10.1177/13524585221102584
Regueiro M, Siegmund B, Yarur AJ, Steinwurz F, Gecse KB, Goetsch M, et al. Etrasimod for the treatment of ulcerative colitis: analysis of infection events from the ELEVATE UC Clinical Program. J Crohns Colitis. 2024. doi:10.1093/eccojcc/jjae060
Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS Study. J Crohns Colitis. 2021;15(6):950-959. doi:10.1093/ecco-jcc/jjab016
Jones JL, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, et al. Canadian Association of GastroenterologyClinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines. J Can Assoc Gastroenterol. 2021;4(4):e72-e91. doi:10.1093/jcag/gwab016
Hastings R, Ding T, Butt S, Gadsby K, Zhang W, Moots RJ, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010;62(6):764-769. doi:10.1002/acr.20037
Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: nonmalignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012;36(4):312-323. doi:10.1111/j.1365-2036.2012.05189.x
Winter RW, Friedman S, Nielsen J, Kjeldsen J, Nørgård BM, Larsen MD. Infliximab is not associated with a general long-term weight gain in patients with inflammatory bowel disease: a nationwide study. Am J Gastroenterol. 2022;117(5):777-784. doi:10.14309/ajg.0000000000001721
Csontos Á A, Molnár A, Piri Z, Katona B, Dakó S, Pálfi E, et al. The effect of anti-TNFα Induction therapy on the nutritional status and dietary intake in inflammatory bowel disease. J Gastrointestin Liver Dis. 2016;25(1):49-56. doi:10.15403/jgld.2014.1121.251.tnf
Davies SC, Nguyen TM, Parker CE, MacDonald JK, Jairath V, Khanna R. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2019;12(12):Cd012804. doi:10.1002/14651858.CD012804. pub2
Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, et al. IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's Disease. J Crohns Colitis. 2020;14(1):23-32. doi:10.1093/ecco-jcc/jjz110
Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113-2128. doi:10.1016/s0140-6736(22)00581-5
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159-1171. doi:10.1016/s0140-6736(23)00061-2
Panhwar MS, Mansoor E, Al-Kindi SG, Sinh P, Katz J, Oliveira GH, et al. Risk of myocardial infarction in inflammatory bowel disease: a population-based National study. Inflamm Bowel Dis. 2019;25(6):1080-1087. doi:10.1093/ibd/izy354
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-1695. doi:10.1056/NEJMra043430
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderateto-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-3140. doi:10.1161/01. Cir.0000077913.60364.D2
Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138(10):807-811. doi:10.7326/0003-4819-138-10-200305200-00008
Vuyyuru SK, Solitano V, Hogan M, MacDonald JK, Zayadi A, Parker CE, et al. Efficacy and safety of IL-12/23 and IL-23 inhibitors for Crohn's disease: systematic review and metaanalysis. Dig Dis Sci. 2023;68(9):3702-3713. doi:10.1007/s10620-023-08014-z
Sandborn WJ, Su C, Panes J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;377(5):496-497. doi:10.1056/NEJMc1707500
Sleutjes JAM, Roeters van Lennep JE, van der Woude CJ, de Vries AC. Lipid changes after induction therapy in patients with inflammatory bowel disease: effect of different drug classes and inflammation. Inflamm Bowel Dis. 2023;29(4):531-538. doi:10.1093/ibd/izac100
Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV, Jr., Hart A, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022;55(4):464-478. doi:10.1111/apt.16712
Adorni MP, Papotti B, Borghi MO, Raschi E, Zimetti F, Bernini F, et al. Effect of the JAK/STAT inhibitor tofacitinib on macrophage cholesterol metabolism. Int J Mol Sci. 2023;24(16). doi:10.3390/ijms241612571
Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022;28(1):32-40. doi:10.1093/ibd/izab011
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326. doi:10.1056/NEJMoa2109927
Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023;82(7):901-910. doi:10.1136/ard-2022-223715
Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82(1):119-129.doi:10.1136/ard-2022-222259
Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECTCOMPARE study. RMD Open. 2022;8(1). doi:10.1136/rmdopen-2021-002012
Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375(9715):657-663.doi:10.1016/s0140-6736(09)61963-2
Bernstein CN, Nugent Z, Singh H. Persistently high rate of venous thromboembolic disease in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2021;116(7):1476-1484. doi:10.14309/ajg.0000000000001237
Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(12):857-873. doi:10.1038/s41575-021-00492-8
Nguyen GC, Elnahas A, Jackson TD. The impact of preoperative steroid use on short-term outcomes following surgery for inflammatory bowel disease. J Crohns Colitis. 2014;8(12):1661-1667. doi:10.1016/j.crohns.2014.07.007
Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford). 2021;61(1):121-130. doi:10.1093/rheumatology/keab294
Ma C, Panaccione R, Xiao Y, Khandelwal Y, Murthy SK, Wong ECL, et al. REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD Research ConsortiumMulticenter National Cohort Study. Am J Gastroenterol. 2023;118(5):861-871. doi:10.14309/ajg.0000000000002129
Lopetuso LR, Mocci G, Marzo M, D'Aversa F, Rapaccini GL, Guidi L, et al. Harmful effects and potential benefits of antitumor necrosis factor (TNF)-α on the liver. Int J Mol Sci. 2018;19(8). doi:10.3390/ijms19082199
Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol. 2021;33(5):623-630. doi:10.1097/meg.0000000000002076
Kunchok A, Aksamit AJ, Jr., Davis JM, 3rd, Kantarci OH, Keegan BM, Pittock SJ, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol. 2020;77(8):937-946.doi:10.1001/jamaneurol.2020.1162
Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum. 2010;62(11):3191-3195.doi:10.1002/art.27687
Chow S, Patnana S, Gupta NK. Posterior Reversible encephalopathy syndrome in a patient with Crohn's disease on infliximab. J Clin Gastroenterol. 2016;50(8):687.doi:10.1097/mcg.0000000000000557
Çimen Güneş E, Çolak S, Tekgöz E, Çınar M, Yılmaz S. Golimumab-induced posterior reversible encephalopathy syndrome (PRES): a case-based review. Clin Rheumatol. 2023;42(12):3407-3410. doi:10.1007/s10067-023-06771-w
Jordan A, Kinnucan J. Ustekinumab-associated posterior reversible encephalopathy syndrome in a patient with Crohn's disease. ACG Case Rep J. 2022;9(10):e00867.doi:10.14309/crj.0000000000000867
Mishra A, Seril DN. Posterior reversible encephalopathy syndrome following ustekinumab induction for Crohn's disease. Case Rep Gastroenterol. 2018;12(2):521-527.doi:10.1159/000492462
Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20(2):119-130. doi:10.1002/pds.2046
Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and antitumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(1):58-64. doi:10.1016/j.cgh.2015.07.037
Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svanström H, Caspersen S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. Jama.2014;311(23):2406-2413. doi:10.1001/jama.2014.5613
Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016;87(5):468-475.doi:10.1136/jnnp-2015-310597
Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, et al. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the Global Clinical Programme. J Crohns Colitis. 2023;17(3):338-351. doi:10.1093/ecco-jcc/jjac141
Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82(3):331-343. doi:10.1136/ard-2022-222543
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian IBD Today 2024
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
